Another senolytic, acting as an mTOR inhibitor, Temsirolimus, has been tested in combination with rituximab in a Phase II clinical trial in diffuse large B cell lymphoma [83] (NCT01653067) and in combination with capecitabine chemotherapy in Phase I clinical trial in advanced solid tumors [84] (NCT01050985). Here, MTOR is linked to diffuse large B-cell lymphoma.